Physician profile
Arpad S Fejos
NPI 1528068921
$1,080.47
in general payments reported to CMS, 2019-2025
25 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Neuromuscular Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $128).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $129 · 2021: $34.25 · 2022: $15.75 · 2023: $196 · 2024: $352 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $728.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $728.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $275.25 | 2019-2025 | Orthovisc, Monovisc, Peak |
| Endo USA, INC. | $131.79 | 2024-2025 | Xiaflex |
| Endo Pharmaceuticals INC. | $63.72 | 2020-2024 | Xiaflex |
| Assertio Therapeutics, INC. | $61.65 | 2019 | |
| Si-Bone, INC. | $58.68 | 2024 | |
| Collegium Pharmaceutical, INC. | $56.02 | 2020-2025 | Belbuca, Xtampza |
| Almatica Pharma LLC | $34.25 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $32.20 | 2025 | |
| Dynasplint Systems INC. | $32.14 | 2019 | |
| Ferring Pharmaceuticals INC. | $30.57 | 2019-2020 | |
| Kerecis Limited | $29.71 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Uswm, LLC | $26.48 | 2023 | Zimhi, Lucemyra |
| Smith+Nephew, INC. | $26.01 | 2025 | Pico |
| Abbvie INC. | $25.17 | 2023 | |
| Valinor Pharma, LLC | $22.21 | 2025 | Movantik |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $20.66 | 2024 | Tirosint, Licart |
| Convatec INC. | $20.06 | 2023 | |
| Pacira Therapeutics, INC. | $19.34 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.07 | 2019 | |
| Amgen INC. | $17.63 | 2024 | Krystexxa |
| Biodelivery Sciences International, INC. | $17.59 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $16.57 | 2023 | Seglentis |
| Horizon Therapeutics Plc | $16.01 | 2020 | |
| Bioventus LLC | $15.75 | 2022 | |
| Pfizer INC. | $12.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arpad Fejos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.